BridgeBio Oncology Therapeutics, Inc. Financing Cash Flow
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Financing Cash Flow of $332.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $37.00K, a 99.80% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $295.00K.
- BridgeBio Oncology Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$586.00K, a 1226.92% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $365.44M, a 1747.84% increase year-over-year.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $332.00K 10-Q · filed 2026-08-11 | -$254.00K derived: sum of 3 quarters · filed 2026-08-11 | $365.18M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $295.00K 10-Q · filed 2026-05-12 | -$291.00K derived: sum of 2 quarters · filed 2026-05-12 | $365.14M derived: sum of 3 quarters · filed 2026-05-12 | $384.10M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | -$586.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $364.85M derived: sum of 2 quarters · filed 2026-04-30 | $383.81M derived: sum of 3 quarters · filed 2026-08-11 | $383.40M POS AM · filed 2026-04-30 | ||
| 2025-09-30 | $365.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $384.39M derived: sum of 2 quarters · filed 2026-08-11 | $383.99M 10-Q · filed 2025-11-12 | $384.04M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $18.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $18.55M 10-Q · filed 2026-08-11 | $18.60M derived: sum of 3 quarters · filed 2026-08-11 | $38.38M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$404.00K 10-Q · filed 2026-05-12 | -$352.00K derived: sum of 2 quarters · filed 2026-05-12 | $19.42M derived: sum of 3 quarters · filed 2026-05-12 | $19.42M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $52.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $19.83M derived: sum of 2 quarters · filed 2026-04-30 | $19.83M derived: sum of 3 quarters · filed 2026-04-30 | $206.29M POS AM · filed 2026-04-30 | $186.46M 10-K · filed 2025-03-11 | |
| 2024-09-30 | $19.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $19.78M derived: sum of 2 quarters · filed 2025-11-12 | $206.24M 10-Q · filed 2025-11-12 | $186.46M 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $186.46M 10-Q · filed 2025-08-01 | ||||
| 2024-03-31 | $186.46M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |